Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbst, Roy S., Wu, Yi-Long, John, Thomas, Grohe, Christian, Majem, Margarita, Wang, Jie, Kato, Terufumi, Goldman, Jonathan W., Laktionov, Konstantin, Kim, Sang-We, Yu, Chong-Jen, Vu, Huu Vinh, Lu, Shun, Lee, Kye Young, Mukhametshina, Guzel, Akewanlop, Charuwan, de Marinis, Filippo, Bonanno, Laura, Domine, Manuel, Shepherd, Frances A., Urban, Damien, Huang, Xiangning, Bolanos, Ana, Stachowiak, Marta, Tsuboi, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
CLINICAL TRIAL UPDATES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082285/
https://www.ncbi.nlm.nih.gov/pubmed/36720083
http://dx.doi.org/10.1200/JCO.22.02186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082285/
https://www.ncbi.nlm.nih.gov/pubmed/36720083
http://dx.doi.org/10.1200/JCO.22.02186

Ejemplares similares